In a decisive move to protect the nation’s multi-billion dollar livestock industry, U.S. Secretary of Agriculture Brooke Rollins announced today, February 5, 2026, the launch of a $100 million "New World Screwworm Grand Challenge." The federal initiative is designed to spur rapid innovation in the detection, containment, and
Medical equipment and services company Steris (NYSE:STE). beat Wall Street’s revenue expectations in Q4 CY2025, with sales up 9.2% year on year to $1.50 billion. Its non-GAAP profit of $2.53 per share was in line with analysts’ consensus estimates.
Medical equipment and services company Steris (NYSE:STE).
will be announcing earnings results this Wednesday after market hours. Here’s what to look for.
While profitability is essential, it doesn’t guarantee long-term success.
Some companies that rest on their margins will lose ground as competition intensifies - as Jeff Bezos said, "Your margin is my opportunity".
When Wall Street turns bearish on a stock, it’s worth paying attention.
These calls stand out because analysts rarely issue grim ratings on companies for fear their firms will lose out in other business lines such as M&A advisory.
Mid-cap stocks often strike the right balance between having proven business models and market opportunities that can support $100 billion corporations.
However, they face intense competition from scaled industry giants and can be disrupted by new innovative players vying for a slice of the pie.
As the Q3 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the surgical equipment & consumables - diversified industry, including STERIS (NYSE:STE) and its peers.
As the Q3 earnings season wraps, let’s dig into this quarter’s best and worst performers in the surgical equipment & consumables - diversified industry, including CONMED (NYSE:CNMD) and its peers.
The stocks in this article are all trading near their 52-week highs.
This strength often reflects positive developments such as new product launches, favorable industry trends, or improved financial performance.
When Wall Street turns bearish on a stock, it’s worth paying attention.
These calls stand out because analysts rarely issue grim ratings on companies for fear their firms will lose out in other business lines such as M&A advisory.
Although STERIS (currently trading at $259.38 per share) has gained 7.1% over the last six months, it has trailed the S&P 500’s 14.4% return during that period. This may have investors wondering how to approach the situation.
The S&P 500 (^GSPC) is often seen as a benchmark for strong businesses, but that doesn’t mean every stock is worth owning.
Some companies face significant challenges, whether it’s stagnating growth, heavy debt, or disruptive new competitors.
Wrapping up Q3 earnings, we look at the numbers and key takeaways for the surgical equipment & consumables - diversified stocks, including BD (NYSE:BDX) and its peers.
Shares of medical equipment and services company Steris (NYSE:STE).
jumped 8.6% in the morning session after the company reported strong third-quarter 2025 results that beat expectations and raised its full-year financial outlook. For the quarter, revenues grew nearly 10% from the previous year to $1.46 billion, while adjusted earnings per share increased by 15.4% to $2.47. Both of these key figures surpassed analyst estimates. Looking ahead, STERIS provided a more optimistic forecast, lifting its expected adjusted earnings for the full year to a range of $10.15 to $10.30 per share.
Medical equipment and services company Steris (NYSE:STE). reported revenue ahead of Wall Streets expectations in Q3 CY2025, with sales up 9.9% year on year to $1.46 billion. Its non-GAAP profit of $2.47 per share was 5.1% above analysts’ consensus estimates.
Wall Street bounced back Wednesday after Tuesday's sharp selloff in AI-driven stocks, as investors bought the dip amid solid corporate earnings and growing signs that the Federal Reserve may be nearing another interest rate cut.
